Research summary ·
Quantifying Placebo Effects in Hereditary Ataxia Trials: A Meta-Analysis of Scale for the Assessment and Rating of Ataxia (SARA) Score Changes.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This review measured placebo effects in trials for hereditary ataxia. The outcome was the SARA score. Data came from the placebo groups of trials found in PubMed and ClinicalTrials.gov. The trials included spinocerebellar ataxias and Friedreich's ataxia. Trials lasted 1 to 52 weeks. The team also tested the role of continent, treatment type and trial length.
What they found
Placebo response differed by continent. European trials showed almost no effect. Asian trials showed the largest effect. Device treatments had the strongest placebo effect. Trial length had no significant effect. There was a trend of less effect over time.
What it means for patients
The authors say there is a measurable placebo effect on SARA scores. Treatment type and region changed its strength. They say this suggests a role for patient hopes and cultural factors. They also note a trend, not significant, toward less placebo response in longer trials.
Why it is not certain yet
Results varied a lot between trials. Only trials with variance data were pooled. The authors offer cultural factors as a suggestion, not proof. The trend over time was not significant.
Source
Quantifying Placebo Effects in Hereditary Ataxia Trials: A Meta-Analysis of Scale for the Assessment and Rating of Ataxia (SARA) Score Changes.
PubMed · PMID 41612637We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Friedreich ataxia publications